Arpeggio Biosciences Inc.

Engineering medicine based not on a single target, but on the biological network as a whole. Visit the Arpeggio Website

The University of Colorado Connection

Arpeggio

​Arpeggio Biosciences is a Boulder-based biotechnology company developing a high-throughput transcriptomics platform to map how chemical compounds influence gene expression across entire biological networks. Founded in 2017 by Joey Azofeifa  (CU Boulder BioFrontiers Institute) and Robin Dowell  (CU Boulder BioFrontiers Institute and Molecular, Cellular & Developmental Biology), the company originated from research conducted at CU's BioFrontiers Institute. Arpeggio's platform combines nascent RNA sequencing with machine learning to profile the immediate effects of drugs on gene expression, enabling the discovery of novel therapeutic targets for diseases such as cancer, chronic kidney disease and neurodegeneration. The company has raised over $20 million in funding, including a $17 million Series A round in 2022 led by Builders VC.

Funding Status and Investment Opportunities

In the News

More Startups News

Venture Partners Programs​

Path to Commercialization

Technology Development Funding

U.S. National Science Foundation (NSF)

U.S. National Science Foundation (NSF)

    This page was last updated on May 9, 2025. Please email vpnews@colorado.edu for corrections or updates

The Insider Investor E-Newsletter

The Insider is Venture Partners at CU Boulder's monthly newsletter featuring the latest headlines, news, events, opportunities and emerging innovations from the university. We have several editions for our audiences.

Subscribe to The Insider  

Questions about investment opportunities?

Amy Dodenhoff

Amy Dodenhoff · Director of Venture Development

Contact Amy 

Media Inquiries

For marketing and communication inquiries, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.

For media inquiries, please visit colorado.edu/news/formedia.